Bio Path Holdings Inc. Daily Stock Analysis

Daily Stock Analysis, BPTH, Bio Path Holdings Inc, priceseries

Bio Path Holdings Inc. Daily Stock Analysis
Stock Information
Open
3.58
Close
3.30
High
3.76
Low
3.29
Previous Close
3.58
Daily Price Gain
-0.28
YTD High
4.24
YTD High Date
Jan 4, 2022
YTD Low
3.23
YTD Low Date
Jan 28, 2022
YTD Price Change
-0.85
YTD Gain
-20.48%
52 Week High
10.17
52 Week High Date
Apr 5, 2021
52 Week Low
3.23
52 Week Low Date
Jan 28, 2022
52 Week Price Change
-3.15
52 Week Gain
-48.84%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jun 20. 2017
80.52
Jun 23. 2017
85.60
3 Trading Days
6.31%
Link
LONG
Sep 12. 2017
64.00
Sep 19. 2017
68.50
5 Trading Days
7.03%
Link
LONG
Oct 6. 2017
77.00
Oct 18. 2017
89.75
8 Trading Days
16.55%
Link
LONG
Nov 16. 2018
9.00
Nov 29. 2018
9.83
8 Trading Days
9.23%
Link
LONG
Feb 28. 2019
2.60
Mar 19. 2019
25.54
13 Trading Days
882.24%
Link
LONG
Oct 11. 2019
9.66
Oct 31. 2019
11.26
14 Trading Days
16.57%
Link
LONG
Mar 26. 2020
3.83
Apr 1. 2020
4.06
4 Trading Days
6.14%
Link
LONG
Dec 7. 2020
3.48
Dec 14. 2020
3.72
5 Trading Days
6.97%
Link
LONG
Feb 1. 2021
4.32
Feb 17. 2021
7.44
11 Trading Days
72.28%
Link
LONG
Apr 28. 2021
6.11
Apr 29. 2021
6.42
1 Trading Days
5.07%
Link
Company Information
Stock Symbol
BPTH
Exchange
NasdaqCM
Company URL
http://www.biopathholdings.com
Company Phone
(832) 742-1357
CEO
Peter H. Nielsen
Headquarters
Texas
Business Address
4710 BELLAIRE BOULEVARD, SUITE 210, BELLAIRE, TX 77401
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001133818
About

Bio-Path Holdings, Inc. operates as a biotechnology company which focuses on the development of targeted therapies for acute myeloid leukemia, chronic myeloid leukemia, and other types of cancer. Its drug candidates include prexigebersen and Liposomal Bcl2. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein, and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.

Description

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2, which is in Phase I clinical trial for the treatment of lymphoma. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading